ASH 2023 | Considerations to optimize the outcomes of bispecific antibody treatment in patients with myeloma
Amrita Krishnan, MD, City of Hope, Duarte, CA, speaks on the myeloma patient profiles indicative of enhanced responses to bispecific antibody treatments. To optimize outcomes, it is advantageous for patients to have received fewer previous lines of therapy; the duration between therapies should be considered, and subsequent treatments should target distinct markers. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Stock Options/Ownership-Public Company: Bristol-Myers Squibb Company
Speakers Bureau: Amgen Inc, Bristol-Myers Squibb Company, Takeda Pharmaceuticals USA Inc
Contracted Research: Janssen Biotech
Consultancy: Adaptive Biotechnologies Corporation, Bristol-Myers Squibb Company, GlaxoSmithKline, Regeneron Pharmaceuticals Inc, Sanofi Genzyme
Advisory Committee: Sutro Biopharma
